Industry Symposia


Date Time (BST) Symposium Details
On Demand Access from 25th April  

Astellas Pharma Ltd - Optimising care for patients with acute myeloid leukaemia: The role of the acute leukaemia clinical nurse specialist 

On Demand Access from 25th April  

Bayer - Cancer Associated Thrombosis Protocol

On Demand Access from 25th April  

BMS Celgene - IMNOVID®▼(pomalidomide): a foundation for present and future therapies?

This promotional symposium is intended for healthcare professionals based in the UK and Ireland.

Speakers: Professor Paul Richardson and Dr Karthik Ramasamy
Professor Richardson, renowned triallist in the field of multiple myeloma, will review the science behind and key results from clinical trials examining the efficacy of IMNOVID® (pomalidomide) in patients with relapsed or refractory multiple myeloma (R/RMM). He will discuss the clinical significance of findings from multiple clinical trials evaluating IMNOVID in doublet or triplet therapy, and share the primary analysis results from studies examining the use of IMNOVID with and without a monoclonal antibody. Dr Ramasamy, a leading myeloma clinician in the UK, will then share two case reports from his own clinical practice involving the practical application of IMNOVID as part of therapy for R/RMM. Professor Richardson and Dr Ramasamy will then discuss the presented data and clinical implications as well as common questions around the use of IMNOVID.


▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at: UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Ireland: via HPRA Pharmacovigilance at www.hpra.ie Adverse events should also be reported to Bristol Myers Squibb via: medical.information@bms.com or 0800 731 1736 (UK) | 1 800 749 749 (Ireland).


Please click here to view the Prescribing Information.

2204-GB-2100052 | April 2021

On Demand Access from 25th April  

Takeda - Case based discussion of Hodgkin lymphoma (HL) management: New and established approaches to early stage and relapsed/refractory (R/R) HL

In this symposium our expert faculty will discuss a new approach for managing early stage, unfavourable frontline HL, focussing on how recently published data might impact clinical practice.

The second half of the session will focus on some of the decision-making conundrums faced when treating patients with challenging cases of R/R HL and will provide an opportunity to discuss practical considerations using case study examples.

Agenda:
Welcome and introductions – Dr Wendy Osborne
A new frontline approach for early unfavourable Hodgkin lymphoma – Dr Wendy Osborne
Frontline Hodgkin lymphoma panel discussion
Exploring the options: How do we manage challenging relapsed cases of Hodgkin lymphoma? – Dr George Follows and Dr Sridhar Chaganti
Relapsed/refractory Hodgkin lymphoma panel discussion


Faculty:
Dr Wendy Osborne – Freeman Hospital, Newcastle
Dr George Follows – Cambridge University Teaching Hospitals, Cambridge
Dr Sridhar Chaganti – Queen Elizabeth Hospital, Birmingham

This is a promotional meeting organised and funded by Takeda.
Takeda medicines will be discussed at this meeting.

C-APROM/UKI/ADCE/0048| Date of prep: April 2021| Expiry Date: September 2021

Sunday 25th April 10:30 - 12:00

Sanofi Genzyme On-Demand Symposium 2020: The Holmes and Watson approach to differential diagnosis: Thrombocytopenia and Anaemia

Chaired by Dr Richard Gooding, our speakers take the Holmes and Watson approach to examine the mystery of unexplained thrombocytopenia and anaemia as part of the differential diagnosis process. Using case studies from their clinical practice, they navigate the potential decision-making process.

Join us on this journey and see how our experts find ways of dealing with the conditions they uncover.

This symposium is organised and funded by Sanofi Genzyme and the content is intended for UK HCPS only.

Date of preparation: April 2021
MAT-GB-2101725

Sunday 25th April 13:00 - 14:30

Janssen BMS - Shaping the future of CAR T-cell therapy in multiple myeloma together: Lessons learned from the UK lymphoma experience

In this non-promotional, joint symposium, organised and funded by Celgene, a BMS company and Janssen-Cilag Limited, our expert faculty will review some of the successes and lessons learned from the UK experience of chimeric antigen receptor T cell (CAR T-cell) therapy in lymphoma. Join us as they discuss key practicalities and clinical considerations for how we might best shape the future and optimise the adoption of CAR T service in multiple myeloma to improve patient outcomes. This engaging and interactive session will offer insightful perspectives from the wider multidisciplinary team.


Welcome and introduction
Prof. Graham Jackson (Consultant Haematologist; Newcastle Hospitals NHS Foundation Trust Newcastle University) - Chair

Plenary presentation: Journey of progress in CAR T-cell therapy development and implementation into clinical practice
Dr Graham Collins (Consultant Haematologist; Oxford University Hospitals NHS Trust) and Dr Rakesh Popat (Consultant Haematologist; University College London Hospitals NHS Foundation Trust, London)

Live interactive panel discussion and Q&A: Key Learnings and Clinical Considerations for Streamlining CAR T-cell Therapy Adoption in Multiple Myeloma
Prof. Graham Jackson (Consultant Haematologist; Newcastle Hospitals NHS Foundation Trust Newcastle University), Dr Rakesh Popat (Consultant Haematologist; University College London Hospitals NHS Foundation Trust, London), Dr Graham Collins (Consultant Haematologist; Oxford University Hospitals NHS Trust), Rose Ellard (Cellular Therapy CNS & Lecturer Practitioner; The Royal Marsden NHS Foundation Trust)

Conclusions and meeting close
Prof. Graham Jackson (Consultant Haematologist; Newcastle Hospitals NHS Foundation Trust Newcastle University)

Date of preparation: April 2021
Document no: EM-57137

 

Sunday 25th April 14:45 - 16:15 Pfizer Haematology Business - Unravelling therapeutic challenges in patients with Leukaemia (AML, CML, and ALL) 
Sunday 25th April 16:30 - 18:00 Novartis - The burden of vaso-occlusive crises in patients with sickle cell disease
Sunday 25th April 16:30 - 18:00

Novartis - Myeloproliferative Neoplasms (MPN): The importance of the multidisciplinary team (MDT) in patient management

Monday 26th April 08:30 - 10:00

Sanofi Genzyme - NEW ADVANCES IN THE TREATMENT OF iTTP - WHAT ARE THE REAL-WORLD IMPLICATIONS?
This is a promotional symposium organised and funded by Sanofi.

For Prescribing and Adverse Event reporting information, click here

Chair: Professor Marie Scully, University College London Hospitals NHS Foundation Trust and University College London

WELCOME AND INTRODUCTIONS – ENTERING A NEW ERA IN iTTP in the UK
Professor Marie Scully

HOW TO DIAGNOSE EARLY
Dr Richard Gooding, Leicester Haemophilia Centre

SPEED OF TREATMENT INITIATION
Dr Rory McCulloch, Gloucestershire Hospitals NHS Foundation Trust

CABLIVI®(caplacizumab) - UK REAL WORLD EXPERIENCE
Dr Matt Stubbs, University College London Hospitals NHS Foundation Trust
Dr Rebecca Shaw, Royal Liverpool and Broadgreen University Hospitals

IMPROVEMENTS IN FOLLOW-UP
Dr Mari Thomas, University College London Hospitals NHS Foundation Trust

QUESTIONS & ANSWERS
Facilitated by Professor Marie Scully

CLOSING REMARKS
Professor Marie Scully

MAT-GB-2100873 (V1.0)

Date of prep: March 2021

Monday 26th April 10:15 - 11:45 Incyte - Challenges in the management of DLBCL in 2021

Monday 26th April 13:00 - 14:30

Novartis - The road so far with CAR-T and where do we go next?

Tuesday 27th April 09:00 - 10:30

Sanofi Genzyme - The kidney matters in Relapsed Refractory Multiple Myeloma (RRMM)

Tuesday 27th April 13:00 - 14:30

AstraZeneca - Unlocking new options for patients with CLL

Tuesday 27th April 14:45 - 16:15 Novartis - I-WISh to improve the HCP-patient dialogue
Tuesday 27th April 16:30 - 18:00 Kite, A Gilead Company - CAR T in the UK: Reaching new indications in B-cell malignancies
Wednesday 28th April 10:15 - 11:45

Jazz - Optimising care for fit patients with high-risk AML*
This promotional symposium has been fully organised and funded by Jazz Pharmaceuticals

Welcome & Introduction to high-Risk AML - Dr Amit Patel, The Christie NHS Foundation Trust
Dr Patel will provide an overview of the high-risk AML landscape, including definition, unmet needs, and the role of Vyxeos Liposomal (Daunorubicin & Cytarabine)

Vyxeos Liposomal: Outcomes in Real-World Settings - Prof Thomas Cluzeau, Central University Hospital of Nice
Learn about the latest real-world evidence for Vyxeos Liposomal from centres in France and Italy and gain insight into the best practice use of haematopoietic stem-cell transplantation in high-risk AML across Europe as Prof Cluzeau presents a relevant patient case study

Quality of Life (QoL) in AML Patients Undergoing Intensive Chemotherapy - Dr Sree Munisamy, Kent and Canterbury Hospital
Dr Munisamy will present the case of a patient who developed COVID-19 during their treatment, followed by quality of life data for Vyxeos Liposomal

Q&A - chaired by Dr Amit Patel , The Christie NHS Foundation Trust
Questions can be submitted via the webinar platform to the speakers during the live event


*high-risk AML defined as therapy-related AML and AML with myelodysplasia related changes
Vyxeos Liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Prescribing Information and Adverse Event reporting can be found here

Date of preparation: April 2021
Job number: UK-VYX-2100099

Wednesday 28th April 13:00 - 14:30 Beigene - Expert Discussion: Current Advances in the Management of Waldenstrom Macroglobulinaemia

Wednesday 28th April 14:45 - 16:15 Astellas Pharma Ltd - Managing FLT3mut+ R/R AML in 2021: How to navigate the evolving treatment landscape
Wednesday 28th April 16:30 - 18:00 Pfizer Hospital Business - Management of bacterial and fungal infections in haematology-oncology patients